.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
US Army
Cerilliant
Julphar
Covington
Deloitte
Harvard Business School
Healthtrust
Queensland Health
AstraZeneca

Generated: July 23, 2017

DrugPatentWatch Database Preview

Hoffmann-la Roche Company Profile

« Back to Dashboard

What is the competitive landscape for HOFFMANN-LA ROCHE, and when can generic versions of HOFFMANN-LA ROCHE drugs launch?

HOFFMANN-LA ROCHE has two approved drugs.

There are three US patents protecting HOFFMANN-LA ROCHE drugs.

There are fifty-two patent family members on HOFFMANN-LA ROCHE drugs in thirty-one countries.

Summary for Applicant: Hoffmann-la Roche

Patents:3
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann-la Roche
ALECENSA
alectinib hydrochloride
CAPSULE;ORAL208434-001Dec 11, 2015RXYesYes► Subscribe► Subscribe
Hoffmann-la Roche
ALECENSA
alectinib hydrochloride
CAPSULE;ORAL208434-001Dec 11, 2015RXYesYes► Subscribe► Subscribe
Hoffmann-la Roche
ALECENSA
alectinib hydrochloride
CAPSULE;ORAL208434-001Dec 11, 2015RXYesYes9,440,922► SubscribeY ► Subscribe
Hoffmann-la Roche
ALECENSA
alectinib hydrochloride
CAPSULE;ORAL208434-001Dec 11, 2015RXYesYes9,365,514► SubscribeY ► Subscribe
Hoffmann-la Roche
INVIRASE
saquinavir mesylate
TABLET;ORAL021785-001Dec 17, 2004RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Hoffmann-la Roche

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hoffmann-la Roche
INVIRASE
saquinavir mesylate
TABLET;ORAL021785-001Dec 17, 20045,196,438*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Hoffmann-la Roche Drugs

Country Document Number Estimated Expiration
Morocco33418► Subscribe
South Africa201106938► Subscribe
EcuadorSP12011573► Subscribe
Australia2010259588► Subscribe
Argentina077025► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Hoffmann-la Roche Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/1996Austria► SubscribePRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
C0044Belgium► SubscribePRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
70013Netherlands► SubscribePRODUCT NAME: SAQUINAVIR DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
C0048Belgium► SubscribePRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
UBS
Accenture
Colorcon
Novartis
Cipla
Healthtrust
Mallinckrodt
Medtronic
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot